Tanvex BioPharma, Inc. (TPE:6541)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
63.30
-0.30 (-0.47%)
Apr 2, 2025, 1:30 PM CST

Tanvex BioPharma Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Revenue
34.6861.4122.45.410.3
Upgrade
Revenue Growth (YoY)
-43.53%174.11%314.43%1702.00%-
Upgrade
Cost of Revenue
26.391.7141.751.860.16
Upgrade
Gross Profit
8.2959.7-19.353.550.14
Upgrade
Selling, General & Admin
306.52453.71234.74219.21239.12
Upgrade
Research & Development
1,0591,7071,3511,3841,861
Upgrade
Operating Expenses
1,3652,1601,5861,6032,100
Upgrade
Operating Income
-1,357-2,101-1,606-1,599-2,100
Upgrade
Interest Expense
-53.34-57.38-54.72-46.22-18.57
Upgrade
Interest & Investment Income
30.1829.049.63.1418.66
Upgrade
Currency Exchange Gain (Loss)
17.981.3212.487.16-5.63
Upgrade
Other Non Operating Income (Expenses)
-19.171.884.2592.851.18
Upgrade
EBT Excluding Unusual Items
-1,381-2,126-1,634-1,542-2,104
Upgrade
Gain (Loss) on Sale of Assets
0.08-2.87-7.21-0.94-0.27
Upgrade
Asset Writedown
--8.67---
Upgrade
Other Unusual Items
-0.190.77---
Upgrade
Pretax Income
-1,381-2,137-1,641-1,543-2,104
Upgrade
Income Tax Expense
0.350.430.020.020.02
Upgrade
Net Income
-1,382-2,137-1,641-1,543-2,104
Upgrade
Net Income to Common
-1,382-2,137-1,641-1,543-2,104
Upgrade
Shares Outstanding (Basic)
15512911810989
Upgrade
Shares Outstanding (Diluted)
15512911810989
Upgrade
Shares Change (YoY)
20.44%9.60%8.31%21.32%9.25%
Upgrade
EPS (Basic)
-8.90-16.58-13.95-14.21-23.51
Upgrade
EPS (Diluted)
-8.90-16.58-13.95-14.21-23.51
Upgrade
Free Cash Flow
-1,257-1,506-1,427-1,417-1,854
Upgrade
Free Cash Flow Per Share
-8.09-11.69-12.14-13.05-20.71
Upgrade
Gross Margin
23.91%97.21%-86.36%65.67%47.67%
Upgrade
Operating Margin
-3912.40%-3420.80%-7166.21%-29581.65%-699859.00%
Upgrade
Profit Margin
-3983.94%-3480.00%-7325.16%-28546.26%-701412.00%
Upgrade
Free Cash Flow Margin
-3623.36%-2452.94%-6370.97%-26208.75%-617884.67%
Upgrade
EBITDA
-1,253-1,976-1,492-1,496-1,958
Upgrade
D&A For EBITDA
103.76124.89113.22102.84141.87
Upgrade
EBIT
-1,357-2,101-1,606-1,599-2,100
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.